In conclusion, our study revealed overexpression of FGFR2 as well as a functional role of FGFR signaling in myxoid liposarcoma and provides basis for the use of FGFR inhibitors as a novel targeted treatment approach for these tumors. This evidence concerns the gene FGFR2 and myxoid liposarcoma.